CES 2025 – L’Oréal unveils a device capable of analyzing skin aging
If we talk about CES for its new products reserved for the world of televisions, computing or even the connected home, the American show welcomes each year a good number of announcements dedicated to health, and even beauty . Among the most active brands in this field, L'Oréal, which formalizes the advances of its laboratories each year. Last year, nothing less than his AirLight Pro hair dryerwhich incorporated infrared technology to care for delicate hair, was shown for the first time. The 2025 edition of the Las Vegas show sees the debut of a device this time dedicated not to hair, but to the skin. At a time when the skincare is more popular than ever – it could be worth some 180 billion dollars in 2025 – this is not surprising.
The Cell BioPrint, by its nickname, is a device intended to carry out a “personalized skin assessment in minutes”indicates L'Oréal, which joined forces to create it with a startup straight from South Korea (NanoEnTek), a mecca of skincare. It relies on proteomics, that is to say on the composition of the proteins of the human body, to determine both the biological age of the skin, the skin's capacity to react to different active ingredients and its manner to evolve over time. The details provided by L'Oréal indicate that its device aims to address skin aging issues: “L’Oréal Cell BioPrint can help anticipate potential cosmetic inconveniences before they are visible, allowing us to act proactively and thus preserve the beauty of our skin”indicates the group, targeting for example pigment spots.
Five minutes for a complete diagnosis
L'Oréal describes a simple operation: the user must apply an adhesive patch to their cheek, add a solution and insert everything into the Cell BioPrint machine. The operation takes five minutes, according to the group, and during this time, L'Oréal offers to complete the reading using its Skin Connect service; thanks to facial photographs and a questionnaire, this service launched in 2023 offers a complementary skin diagnosis.
The Cell BioPrint promises to be a device dedicated to L'Oréal stores, and will also be “launched with a L’Oréal Groupe brand” in Asia during this year 2025. Even if the firm highlights its ability to isolate active ingredients useful for skin care, it is therefore a safe bet that the device will focus on advising cosmetic products from the group.
